Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Guangzhou
Clinical trial register · China

Clinical Trials in Guangzhou, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19187 matching records held by the registry are in this view. Synced 07 Nov 2026, 03:17 UTC
19187
Studies in scope
all four open statuses
11790
Recruiting now
open to new participants
2028
Lead sponsors
across recruiting studies
Top sites
Guangzhou 44 Beijing 38 Shanghai 26 Fuzhou 20 Hangzhou 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Sun Yat-sen University12 AstraZeneca7 Second Affiliated Hospital of Guangzhou Medical University6 Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University2 Hoffmann-La Roche2
Site location
Guangzhou44 Beijing38 Shanghai26 Fuzhou20 Hangzhou18
All 57 locations
Target enrolment
to

Trials with a site in Guangzhou

44 of 19187 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
West China Hospital
Not applicable
60
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Nanjing, Shanghai
2026-12-01
Not yet open
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
20
Guangzhou
2026-06-22
Recruiting
Binkui Li
Phase 3
300
Guangzhou
2026-05-15
Recruiting
Sintilimab Plus Bevacizumab Biosimilar as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma
NCT07324824Hepatocellular Carcinoma, Neoadjuvant Therapy, Sintilimab, Bevacizimab
DrugsBevacizumab biosimilar·Sintilimab
Sun Yat-sen University
Phase 2
37
Guangzhou
2026-01-14
Active, closed
AstraZeneca
Phase 2
114
Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Jinan, Nanjing
2025-08-05
Recruiting
AstraZeneca
Phase 1/2
304
Chengdu, Guangzhou, Harbin, Shanghai
2025-03-27
Recruiting
Fruquintinib After ICIs Treatment in Unresectable Hepatocellular Carcinoma
NCT06446154Hepatocellular Carcinoma, Immune Checkpoint Inhibitors, Anti-angiogenic Therapy, Second-line Treatment
DrugFruquintinib
Sun Yat-sen University
Phase 2
36
Guangzhou
2024-12-27
Recruiting
Neoadjuvant HAIC and PD-1 Plus Adjuvant PD-1 for High-risk Recurrent HCC
NCT06467799Hepatocellular Carcinoma, Beyond Milan Criteria
Sun Yat-sen University
Phase 2
39
Guangzhou
2024-09-01
Recruiting
Plasma Sphingolipid Metabolites and Radiotherapy Efficacy in Hepatocellular Carcinoma
NCT06864221Hepatocellular Carcinoma, Radiotherapy, Treatment Outcome, Biomarkers
Nanfang Hospital, Southern Medical University
Observational
260
Guangzhou
2024-09-01
Recruiting
Postoperative Adjuvant Therapy of Donafenib for Hepatocellular Carcinoma
NCT06581315Hepatocellular Carcinoma, Adjuvant Therapy
DrugDonafenib
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Not applicable
204
Guangzhou
2024-08-28
Recruiting
Nanfang Hospital, Southern Medical University
Observational
900
Guangzhou
2024-07-01
Recruiting
Sun Yat-sen University
Phase 2
140
Guangzhou
2024-04-05
Not yet open
Value of Dynamic Monitoring of Early Recurrence of Hepatocellular Carcinoma After Radical Resection Based on CTCS
NCT06317896Hepatocellular Carcinoma, Circulating Tumor Cell, Recurrence, Surgery
Zhujiang Hospital
Observational
82
Foshan, Guangzhou
2024-04-01
Recruiting
Mian XI
Phase 2
60
Guangzhou
2024-03-10
Recruiting
ITGA6 Targeting NIR-II Fluorescence Image Guided Surgery
NCT06204835Hepatocellular Carcinoma
Institute of Automation, Chinese Academy of Sciences
Phase 1
90
Guangzhou, Luzhou
2024-01-07
Recruiting
Sun Yat-sen University
Phase 3
200
Guangzhou
2023-12-26
Recruiting
Concurrently vs Sequentially Combined HAIC With Targeted and Immunotherapy in Potentially Resectable HCC
NCT06041477Hepatocellular Carcinoma, Chemotherapy Effect, Chemotherapeutic Toxicity
Sun Yat-sen University
Phase 3
540
Guangzhou
2023-10-31
Active, closed
Hoffmann-La Roche
Phase 3
687
Baoji, Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou
2023-09-14
Recruiting
Guangdong Provincial People's Hospital
Phase 2
29
Guangzhou
2023-09-01
Recruiting
Sun Yat-sen University
Phase 2
43
Guangzhou
2023-09-01
Recruiting
TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT
NCT05984511Hepatocellular Carcinoma, Hepatic Portal Vein Tumor Invasion, Tumor Thrombus
DrugsAtezolizumab·Bevacizumab
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
234
Guangzhou
2023-08-30
Recruiting
SIRT for Potentially Resectable HCC
NCT05994859Hepatocellular Carcinoma
Second Affiliated Hospital of Guangzhou Medical University
Not applicable
35
Guangzhou
2023-08-10
Recruiting
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 2
59
Guangzhou
2023-06-21
Recruiting
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
480
Bengbu, Hefei, Beijing, Chongqing, Fuzhou, Lanzhou, Guangzhou, Nanning
2023-05-10
Active, closed
AstraZeneca
Phase 2
294
Beijing, Chengdu, Chongqing, Fuzhou, Guangzhou, Harbin, Nanning, Shanghai
2023-04-24
Recruiting
Sun Yat-sen University
Phase 2
55
Guangzhou
2023-03-09
Active, closed
AstraZeneca
Phase 3
214
Beijing, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan
2023-02-15
Recruiting
Efficacy and Safety of ALSS Treatment for ICIs-LF in Patients With HCC
NCT05484908Immune-Mediated Hepatitis, Liver Failure, Hepatocellular Carcinoma
Third Affiliated Hospital, Sun Yat-Sen University
Not applicable
60
Guangzhou
2022-08-12
Active, closed
AstraZeneca
Phase 3
760
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Haikou, Hangzhou
2022-03-28
Active, closed
Sun Yat-sen University
Phase 3
214
Guangzhou
2022-01-17
Recruiting
Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors
NCT05024214Solid Tumors, Non-small Cell Lung Cancer, Renal Cell Carcinoma, Hepatocellular Carcinoma
DrugsEnvafolimab·Sunitinib·Lenvatinib
3D Medicines (Sichuan) Co., Ltd.
Phase 1/2
170
Bengbu, Beijing, Fuzhou, Xiamen, Dongguan, Guangzhou, Zhuhai, Haerbin
2021-11-15
Active, closed
Hoffmann-La Roche
Phase 3
342
Anhui, Beijing, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou
2021-03-12
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
50
Guangzhou
2021-03-01
Recruiting
Sun Yat-sen University
Not applicable
320
Guangzhou
2021-02-20
Recruiting
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
100
Guangzhou
2021-01-01
Recruiting
Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs
NCT04770207Hepatocellular Carcinoma, Solid Tumor, Adult
Second Affiliated Hospital of Guangzhou Medical University
Phase 2
100
Guangzhou
2020-11-01
Active, closed
CStone Pharmaceuticals
Phase 3
534
Bengbu, Hefei, Beijing, Fuzhou, Xiamen, Foshan, Guangzhou, Nanning
2019-12-13
Active, closed
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
NCT06239155Advanced Solid Tumors, Hepatocellular Carcinoma
DrugAST-3424
Ascentawits Pharmaceuticals, Ltd
Phase 1/2
51
Guangzhou, Zhengzhou, Nanjing, Shenyang, Shanghai, Hangzhou
2019-09-03
Active, closed
Sun Yat-sen University
Phase 2
40
Guangzhou
2019-03-25
Active, closed
AstraZeneca
Phase 3
724
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2018-11-30
Active, closed
Exelixis
Phase 3
837
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Nanjing
2018-06-10
Active, closed
AstraZeneca
Phase 3
1,324
Beijing, Changchun, Changsha, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou
2017-10-11
Recruiting
GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
NCT03198546Hepatocellular Carcinoma, Immunotherapy, CAR, GPC3 Gene Inactivation
Second Affiliated Hospital of Guangzhou Medical University
Phase 1
30
Guangzhou
2017-07-01
Recruiting
Sun Yat-sen University
Phase 3
230
Guangzhou
2016-01-01
Rows per page Showing 1–44 of 44
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 7 November 2026. https://priyalifescience.com/clinical-trials-china/city/guangzhou

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,187 studies in total at the last sync on 07 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 44 of those studies with a site in Guangzhou that also match the filters currently applied.

How many clinical trials are recruiting in Guangzhou?

28 of the 44 studies on this page are recruiting new participants as of the 07 Nov 2026, 03:17 UTC sync. A further 3 have not yet opened recruitment, 13 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Guangzhou), 44 studies
PhaseStudiesRecruitingShare
Phase 2151134.1%
Phase 314531.8%
Not applicable6513.6%
Observational326.8%
Phase 1336.8%
Phase 1/2326.8%

Most active sponsors

Lead sponsors with the most studies (Guangzhou)
Lead sponsorStudiesRecruiting
Sun Yat-sen University1210
AstraZeneca71
Second Affiliated Hospital of Guangzhou Medical University65
Hoffmann-La Roche20
Nanfang Hospital, Southern Medical University22
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University22
Third Affiliated Hospital, Sun Yat-Sen University22
3D Medicines (Sichuan) Co., Ltd.11
Ascentawits Pharmaceuticals, Ltd10
Binkui Li11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.